JIP
SWTX

Jaffetilchin Investment Partners’s SpringWorks Therapeutics SWTX Stock Holding History

Jaffetilchin Investment Partners’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-480
Closed -$15.4K – 1194
2024
Q3 		$15.4K Buy
+480
New +$17.9K ﹤0.01% 816

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Jaffetilchin Investment Partners's SWTX Position: Q4 2024 in Review

Jaffetilchin Investment Partners sold out of SpringWorks Therapeutics (SWTX) in Q4 2024, closing a stake of 480 shares — an estimated $15.4K sold.

Jaffetilchin Investment Partners first reported a position in SWTX in Q3 2024 and held it in 1 quarter. The position peaked at $15.4K in Q3 2024. 216 funds tracked by Wall St. Rank hold SWTX as of Q4 2024.

  • Jaffetilchin Investment Partners reported no remaining SpringWorks Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Jaffetilchin Investment Partners sold 480 SpringWorks Therapeutics shares in Q4 2024, an estimated $15.4K.
  • Jaffetilchin Investment Partners first reported a position in SpringWorks Therapeutics in Q3 2024 and held it in 1 quarter.
  • Jaffetilchin Investment Partners's SpringWorks Therapeutics position peaked at $15.4K in Q3 2024.
  • 216 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q4 2024.

Based on Jaffetilchin Investment Partners's 13F filing for Q4 2024, filed 13 Feb 2025.